Pulse Biosciences Q3  net loss widens

Pulse Biosciences

05/11/2025 22:01

Overview

Pulse Biosciences Q3 2025 revenue was $86 thousand, marking limited market release start

GAAP net loss for Q3 widened to $19.4 mln from $12.7 mln last year

Increased expenses due to expanding organization for clinical trials and commercialization

Result Drivers

LIMITED MARKET RELEASE - Generated $86 thousand in revenue from the limited market release of nPulse Vybrance system

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$19.39 mln
Q3 Income from Operations
-$20.37 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Pulse Biosciences Inc is $22.00, about 27% above its November 4 closing price of $16.06

Press Release: ID:nBw5XpvnHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)